Yahoo1mon
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...
Hosted on MSN2mon
Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss
Hines Jr Professor of Medicine at Yale University School of Medicine Tirzepatide decreases heart size to improve cardiac structure, function In a secondary analysis of the SUMMIT trial ...